Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Steven J Cohen; Linus Ho; Sulabha Ranganathan; James L Abbruzzese; R Katherine Alpaugh; Mary Beard; Nancy L Lewis; Susan McLaughlin; André Rogatko; Juan J Perez-Ruixo

doi:10.1200/JCO.2003.08.040

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Identifier:nobleid.org/w1/20260515/3CD05959

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3CD05959.svg?ark=w1%2F20260515%2F3CD05959)](https://nobleid.org/work/w1/20260515/3CD05959)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Identifier:nobleid.org/w1/20260515/3CD05959

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3CD05959.svg?ark=w1%2F20260515%2F3CD05959)](https://nobleid.org/work/w1/20260515/3CD05959)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work